These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 32142835)
1. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835 [TBL] [Abstract][Full Text] [Related]
2. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. McKenney JK; Desai S; Cohen C; Amin MB Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293 [TBL] [Abstract][Full Text] [Related]
3. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mallofré C; Castillo M; Morente V; Solé M Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096 [TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells. Bahceci D; Nguyen JK; Sangoi AR; Stohr BA; Chan E Hum Pathol; 2023 Jun; 136():56-62. PubMed ID: 36997033 [TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ. Straccia P; Fiorentino V; Martini M; Pierconti F Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):521-530. PubMed ID: 36216762 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526 [TBL] [Abstract][Full Text] [Related]
9. [A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens]. Russo S; Botti G; Vinaccia P; Iaccarino C; Maioli S; Del Prete D; Maiello FM Pathologica; 2007 Apr; 99(2):46-9. PubMed ID: 17633807 [TBL] [Abstract][Full Text] [Related]
10. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Broussard JN; Tan PH; Epstein JI Hum Pathol; 2004 Dec; 35(12):1499-504. PubMed ID: 15619209 [TBL] [Abstract][Full Text] [Related]
11. Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases. Sangoi AR; Falzarano SM; Nicolas M; McKenney JK Am J Surg Pathol; 2019 Dec; 43(12):1638-1643. PubMed ID: 31368912 [TBL] [Abstract][Full Text] [Related]
12. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Kunju LP; Lee CT; Montie J; Shah RB Pathol Int; 2005 May; 55(5):248-54. PubMed ID: 15871722 [TBL] [Abstract][Full Text] [Related]
13. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study]. Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826 [TBL] [Abstract][Full Text] [Related]
14. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670 [TBL] [Abstract][Full Text] [Related]
15. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma. Mai KT; Busca A; Belanger EC Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746 [TBL] [Abstract][Full Text] [Related]
16. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67. Asgari M; Nabi Maybodi M; Abolhasani M Med J Islam Repub Iran; 2016; 30():400. PubMed ID: 27579290 [TBL] [Abstract][Full Text] [Related]
17. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464 [TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Yin H; He Q; Li T; Leong AS Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):260-5. PubMed ID: 16932015 [TBL] [Abstract][Full Text] [Related]
19. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions? Di Sciascio L; Ambrosi F; Franceschini T; Giunchi F; Franchini E; Massari F; Bianchi FM; Colecchia M; Fiorentino M; Ricci C Pathol Res Pract; 2022 Jun; 234():153937. PubMed ID: 35561522 [TBL] [Abstract][Full Text] [Related]
20. CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia. Arias-Stella JA; Shah AB; Gupta NS; Williamson SR Arch Pathol Lab Med; 2018 Jan; 142(1):64-69. PubMed ID: 28967804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]